Integra LifeSciences Competitors

Abbott Laboratories (NYSE:ABT) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Insider and Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 4.3% of Integra LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Abbott Laboratories and Integra LifeSciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Abbott Laboratories and Integra LifeSciences' revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Abbott Laboratories and Integra LifeSciences, as provided by MarketBeat.com.

Abbott Laboratories currently has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Integra LifeSciences has a consensus target price of $55.9167, suggesting a potential upside of 2.07%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, research analysts clearly believe Abbott Laboratories is more favorable than Integra LifeSciences.

Risk and Volatility

Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Summary

Abbott Laboratories beats Integra LifeSciences on 10 of the 14 factors compared between the two stocks.

Integra LifeSciences (NASDAQ:IART) and Medtronic (NYSE:MDT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for Integra LifeSciences and Medtronic, as reported by MarketBeat.

Integra LifeSciences currently has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Medtronic has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Given Medtronic's stronger consensus rating and higher possible upside, analysts plainly believe Medtronic is more favorable than Integra LifeSciences.

Earnings & Valuation

This table compares Integra LifeSciences and Medtronic's top-line revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Integra LifeSciences and Medtronic's net margins, return on equity and return on assets.

Volatility & Risk

Integra LifeSciences has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Institutional and Insider Ownership

84.9% of Integra LifeSciences shares are held by institutional investors. Comparatively, 79.9% of Medtronic shares are held by institutional investors. 4.3% of Integra LifeSciences shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Medtronic beats Integra LifeSciences on 10 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Stryker and Integra LifeSciences, as reported by MarketBeat.com.

Stryker presently has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Integra LifeSciences has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Given Integra LifeSciences' higher possible upside, analysts plainly believe Integra LifeSciences is more favorable than Stryker.

Valuation & Earnings

This table compares Stryker and Integra LifeSciences' top-line revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Integra LifeSciences' net margins, return on equity and return on assets.

Volatility & Risk

Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 4.3% of Integra LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Stryker beats Integra LifeSciences on 11 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 4.3% of Integra LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Intuitive Surgical and Integra LifeSciences, as reported by MarketBeat.com.

Intuitive Surgical presently has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Integra LifeSciences has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Given Integra LifeSciences' higher possible upside, analysts plainly believe Integra LifeSciences is more favorable than Intuitive Surgical.

Volatility & Risk

Intuitive Surgical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Valuation & Earnings

This table compares Intuitive Surgical and Integra LifeSciences' top-line revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intuitive Surgical and Integra LifeSciences' net margins, return on equity and return on assets.

Summary

Intuitive Surgical beats Integra LifeSciences on 10 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Insider and Institutional Ownership

74.4% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are owned by institutional investors. 0.1% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 4.3% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Becton, Dickinson and and Integra LifeSciences, as reported by MarketBeat.com.

Becton, Dickinson and presently has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Integra LifeSciences has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Given Becton, Dickinson and's stronger consensus rating and higher possible upside, equities analysts clearly believe Becton, Dickinson and is more favorable than Integra LifeSciences.

Risk and Volatility

Becton, Dickinson and has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Valuation and Earnings

This table compares Becton, Dickinson and and Integra LifeSciences' top-line revenue, earnings per share (EPS) and valuation.

Becton, Dickinson and has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Becton, Dickinson and and Integra LifeSciences' net margins, return on equity and return on assets.

Summary

Becton, Dickinson and beats Integra LifeSciences on 10 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Insider and Institutional Ownership

79.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 4.3% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Edwards Lifesciences and Integra LifeSciences, as reported by MarketBeat.com.

Edwards Lifesciences presently has a consensus price target of $87.7222, suggesting a potential upside of 3.57%. Integra LifeSciences has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Edwards Lifesciences is more favorable than Integra LifeSciences.

Risk and Volatility

Edwards Lifesciences has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Valuation and Earnings

This table compares Edwards Lifesciences and Integra LifeSciences' top-line revenue, earnings per share (EPS) and valuation.

Edwards Lifesciences has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Integra LifeSciences' net margins, return on equity and return on assets.

Summary

Edwards Lifesciences beats Integra LifeSciences on 9 of the 14 factors compared between the two stocks.